Platelet reactivity characterized prospectively: A determinant of outcome 90 days after percutaneous coronary intervention

Circulation

Volumn 104, Issue 2, 2001, Pages 181-186

  Kabbani, Samer S ^a,b   Watkins, Matthew W ^a   Ashikaga, Taka ^a   Terrien, Edward F ^a   Holoch, Peter A ^a   Sobel, Burton E ^a   Schneider, David J ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b FLETCHER ALLEN HEALTH CARE   (United States)

Author keywords

Angioplasty; Complications; Platelets; Restenosis

Indexed keywords

FIBRINOGEN RECEPTOR;

ADULT; AGED; ARTICLE; FEMALE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HEART SURGERY; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; SURGICAL APPROACH; THROMBOCYTE ACTIVATION;

EID: 0035838355     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.104.2.181     Document Type: Article

References (28)

1. The pathogenesis of coronary artery disease and the acute coronary syndromes
2. Integrins: A family of cell surface receptors
3. Regulation of vascular integrins
4. Platelets in cardiovascular thrombosis and thrombolysis
5. Platelet hyperreactivity and prognosis in survival of myocardial infarction
6. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade: The EPISTENT Investigators: Evaluation of platelet IIb/IIIa inhibitor for STENTing
7. Randomized placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT II: Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis II
8. Effect of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty: The RESTORE Investigators: Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis
9. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction
10. Production of monoclonal antibodies specific for platelet activation antigens and their use in evaluating platelet function
11. Differential effects of anticoagulants on the activation of platelet ex vivo
12. Flow cytometry: A clinical test of platelet function
13. Differences between activation thresholds for platelet p-selectin and glycoprotein IIb-IIIa expression and their clinical implications
14. Variable responses to inhibition of fibrinogen binding induced by tirofiban and eptifibatide in blood from healthy subjects
15. Blood clotting in minimally altered whole blood
16. Optimally functional fluorescein isothiocyanate-labelled fibrinogen for quantitative studies of binding to activated platelets and platelet aggregation
17. Increased reactivity of platelets induced by fibrinogen independent of its binding to the IIb-IIIa surface glycoprotein: A potential contributor to cardiovascular risk
18. A comparison of three-year survival after coronary artery bypass graft surgery and percutaneous transluminal coronary angioplasty
19. Minimal myocardial damage during coronary intervention is associated with impaired outcome
20. Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention
21. Clinical risk factors for ischemic complications after percutaneous coronary interventions: Results from the EPIC trial
22. Comparison of coronary artery bypass surgery with angioplasty in patients with multivessel disease
23. Platelet glycoprotein IIb-IIIa receptors in cardiovascular medicine
24. Platelet membrane activation markers are predictive for increased risk of acute ischemic events after PTCA
25. 1c with prevalent cardiovascular disease in the original cohort of the Framingham Heart Study
26. Platelet abnormalities in diabetes mellitus
27. Plasma fibrinopeptide A levels during insulin-induced plasma glucose falls in diabetics